MARKET

BPTH

BPTH

Bio-Path Hldgs Inc
NASDAQ
2.120
-0.095
-4.29%
Opening 13:32 01/30 EST
OPEN
2.220
PREV CLOSE
2.215
HIGH
2.220
LOW
2.120
VOLUME
24.16K
TURNOVER
11.00K
52 WEEK HIGH
4.478
52 WEEK LOW
1.273
MARKET CAP
16.88M
P/E (TTM)
-1.0831
1D
5D
1M
3M
1Y
5Y
Bio-Path Holdings Doses First Patient in Phase 1/1b Study of BP1001-A in Solid Tumors
Bio-Path Holdings Doses First Patient in Phase 1/1b Study of BP1001-A in Solid Tumors
MT Newswires · 12/07/2022 10:42
Bio-Path Holdings Q3 2022 Earnings Conference Call On November 15, 2022 At 08:30 AM ET
Benzinga · 12/06/2022 17:26
Analyzing Bio-Path Holdings's Short Interest
Benzinga · 11/28/2022 16:37
BRIEF-Bio-Path Holdings Reports Third Quarter 2022 Financial Results
Reuters · 11/15/2022 12:08
Bio-Path GAAP EPS of -$0.49 misses by $0.03
Seekingalpha · 11/15/2022 12:06
Bio-Path Holdings Late Monday Reported Q3 EPS $(0.49) Misses $(0.45) Estimate
Benzinga · 11/15/2022 12:03
Notable earnings before Tuesday's open
Seekingalpha · 11/14/2022 15:47
Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today anno...
GlobeNewswire · 11/08/2022 12:00
More
About BPTH
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company. It utilizes a technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead drug candidate, prexigebersen, targets growth factor receptor-bound protein 2 (Grb2). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein. Its modified product named prexigebersen-A, is its fourth drug candidate.

Webull offers kinds of Bio Path Holdings Inc stock information, including NASDAQ:BPTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPTH stock methods without spending real money on the virtual paper trading platform.